Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02188368|
Recruitment Status : Recruiting
First Posted : July 11, 2014
Last Update Posted : October 5, 2018
The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM).
Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: POM Drug: Steroids Drug: PLD Drug: CFZ Drug: BTZ Drug: CLA Drug: Other drugs Drug: CY||Phase 2|
This is a phase 2, multicenter, open-label and non-randomized study to evaluate the efficacy and safety of pomalidomide as a replacement for lenalidomide among MM patients who have failed lenalidomide-containing regimens that include more than steroids within 6 months of their last dose of lenalidomide. Pomalidomide will replace lenalidomide in a combination regimen containing an alkylating agent (cyclophosphamide), anthracycline (doxorubicin or PLD), proteasome inhibitor (bortezomib or carfilzomib) and/or a glucocorticosteroid (prednisone, dexamethasone or methylprednisolone). Pomalidomide will be administered on days 1-21 of a 28-day cycle, whereas other drugs (anthracyclines, proteasome inhibitors, steroids or alkylating agents except melphalan) will be administered using the same schedule(s), dose(s) and drug combination as the last lenalidomide-containing regimen that the patient received and failed. This study will enroll patients resistant to a lenalidomide-containing combination regimen as demonstrated by PD while being treated or that has relapsed within 6 months of the last dose of lenalidomide in their last lenalidomide-containing combination regimen or while on lenalidomide or lenalidomide and steroid maintenance therapy. Forty-five patients will be enrolled in the study.
The study consists of: 1) a screening period; 2) up to eight 28-day, treatment cycles; 3) a final assessment to occur 28 days after the end of the last treatment cycle; and 4) a follow-up period.
Subjects eligible for this study will receive treatment with study drug for a maximum of eight 28-day treatment cycles, depending on the schedule of their last lenalidomide-containing regimen. Subjects are to be treated to a maximum response (lowest level of paraprotein) plus 1 additional cycle, without exceeding a total of 8 cycles, or complete 8 cycles of therapy without progressing (PD).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||45 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen|
|Study Start Date :||August 2014|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: A: POM 4mg+Steroids+(CFZ, BTZ, CY or CLA)
POM 4 mg PO days 1-21 Steroids at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
CFZ (carfilzomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
CLA (clarithromycin) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
CY (cyclophosphamide) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
Other Name: Clarithromycin
Other Name: Cyclophosphamide
Experimental: B: POM 3mg+PLD with or without steroids
POM 3 mg PO days 1-21 Steroids (if the patient had received them) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
PLD at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
Other Name: Pegylated liposomal doxirrubicin
Experimental: C: POM MTD + other drugs
POM at escalating doses of 2 mg (Cycle 1), 3 mg (Cycle 2) or 4 mg (Cycle 3+) All other agents at the same dose and on the same days as the patients were receiving them in the lenalidomide-containing regimen they had failed
POM at the MTD All other agents, at the same dose and on the same days as phase 1
Drug: Other drugs
- Maximum Tolerated Dose (MTD) [ Time Frame: Cycles 1-3 for selected regimens (up to 3 months) ]
MTD will be determined for any ≥ three-drug combinations other than:
bortezomib + steroids + lenalidomide; carfilzomib + steroids + lenalidomide; clarithromycin + steroids + lenalidomide; cyclophosphamide + steroids + lenalidomide pegylated liposomal doxorubicin (PLD) + lenalidomide with or without steroids
- Number of subjects with adverse events [ Time Frame: up to 36 months ]Adverse events will be graded via the Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 criteria.
- Overall Response Rate [ Time Frame: up to 36 months ]Overall response rate (ORR): complete response (CR)+ very good partial response (VGPR) + partial response (PR)
- Clinical Benefit Rate (CBR) [ Time Frame: up to 36 months ]CBR=ORR + minor response (MR)
- Time to Progression [ Time Frame: time from initiation of therapy to progressive disease (assessed at least over 36 months) ]
- Progression-free survival (PFS) [ Time Frame: time from initiation of therapy to progressive disease or death from any cause, whichever comes first (assessed at least over 36 months) ]
- Time to first response (TTP) [ Time Frame: time from initiation of therapy to the first evidence of a confirmed response (up to 36 months) ]
- Duration of response (DOR) [ Time Frame: time from the first response (> PR) to progressive disease (assessed at least over 36 months) ]
- Overall survival (OS) [ Time Frame: time from initiation of therapy to death from any cause or last follow-up visit (assessed at least over 36 months). ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02188368
|Contact: Noemi Silaganfirstname.lastname@example.org|
|United States, California|
|California Cancer Associates for Research & Excellence (cCARE)||Recruiting|
|Encinitas, California, United States, 92024|
|Contact: Alberto Bessudo, MD|
|Contact: Beth Kimball, RN (760) 452-3909 BKimball@ccare.com|
|Compassionate Care Research Group||Recruiting|
|Fountain Valley, California, United States, 92708|
|Contact: Haresh Jhangiani, MD|
|Contact: Barbara Lepthien (714) 698-0300 email@example.com|
|Comprehensive Cancer Center at Desert Regional Medical Center||Completed|
|Palm Springs, California, United States, 92262|
|Inland Hematology Oncology Medical Group, Inc||Recruiting|
|San Bernardino, California, United States, 92404|
|Contact: Samir Kubba, MD|
|Contact: Emmarin Saribut (909) 886-6806 firstname.lastname@example.org|
|Wellness Oncology and Hematology||Recruiting|
|West Hills, California, United States, 91307|
|Contact: Ashkan Lashkari, MD|
|Contact: Mary Mau (818) 346-1773 email@example.com|
|James R. Berenson, MD, Inc.||Recruiting|
|West Hollywood, California, United States, 90069|
|Contact: Regina Swift, RN 310-623-1222 firstname.lastname@example.org|
|Contact: James R. Berenson, MD 310-623-1214 email@example.com|
|Principal Investigator: James Berenson, MD|
|United States, Nevada|
|VA Sierra Nevada||Completed|
|Reno, Nevada, United States, 89502|
|United States, New Mexico|
|San Juan Oncology Associates||Recruiting|
|Farmington, New Mexico, United States, 87401|
|Contact: Jeffrey Neidhart, MD|
|Contact: Rosemarie Mestas (505) 564-6874 firstname.lastname@example.org|
|United States, Ohio|
|Gabrail Cancer Center||Recruiting|
|Canton, Ohio, United States, 44718|
|Contact: Nashat Gabrail, MD|
|Contact: Kirstie Armstrong (330) 492-3345 email@example.com|
|United States, South Dakota|
|Rapid City Regional Hospital||Completed|
|Rapid City, South Dakota, United States, 57701|
|United States, Tennessee|
|Wellmont Medical Associates Oncology and Hematology||Recruiting|
|Kingsport, Tennessee, United States, 37660|
|Contact: Ibrahim Nakhoul, MD|
|Contact: Justin Reynolds (423) 578-8553 Justin.Reynolds@wellmont.org|
|United States, Washington|
|Olympia, Washington, United States, 98502|
|Principal Investigator:||James R Berenson, MD||James R. Berenson MD, Inc.|